ALKALI METALS LTD
Add to watch list to get report alerts
BSE Code:
533029
NSE Code:
ALKALI
Business Profile
Business Profile
Alkali Metals is an ISO 14001:2004 and ISO 9001:2000 certified company engaged in the business of manufacturing a range of fine chemicals, based on related chemistry. The company was incorporated on April 17, 1968 in a joint venture with APIDC. It commenced the production of sodium metal, with an installed capacity of 125 MT. The company developed the technology for sodium metal based on in-house R & D capabilities. It enjoys a distinction of developing technology for the manufacture of sodium metal for usage in fast breeder nuclear reactors for power generation.
Company?s diversified product portfolio can be classified into the three categories- Sodium derivatives, pyridine derivatives and fine chemicals.
Products in these categories include amides, hydrides, alkoxides, azides, tetrazoles, pyridine compounds, cyclic compounds, drug and pharma intermediates, specialty fine chemicals etc. The company manufactures these products on bulk and regular basis, on campaign basis and also on contract manufacturing basis.
Company?s customer kitty includes some of the leading global pharma majors like Dr. Reddys Laboratories, Aurobindo Pharma, Ranbaxy, Clariant, Novasep and Siber Hegner.
The company also has a dedicated R&D facility recognized by the Ministry of Science and Technology, New Delhi. Currently, the company has two manufacturing facilities, Unit I and II. Both these units are ISO 9001: 2000 and ISO 14001:2004 certified and both are having the installed capacity of 2,200 MTPA each.
While Unit I is engaged in the manufacture of sodium metals, organo alkali metallics, tetrazoles, amino pyridines and caters to the domestic market, Unit II, a 100% EOU is engaged in the manufacture of pyridine derivatives, cyclic compounds and fine chemicals.
The registered office of our Company is located at B-5, Block III, Industrial Development Area, Uppal, Hyderabad-500 039, Andhra Pradesh, India.
Financials
The company registered a marginal increase in its net profit for the year ended March 31, 2008. The profit of the company rose 4.30% to Rs 79.32 million as against Rs 76.05 million for the year ended March 31, 2007. Net Sales rose 2.93% to Rs 617.68 million, while total income for the year rose 2.09% to Rs 653.35 million as against Rs 640 million for the previous year period.
Future Plans
The company plans to set up an Active Pharmaceutical Ingredients (API) plant at Jawaharlal Nehru Pharma City at Visakhapatnam with an installed capacity of 672 MTPA.
It has entered into a sale agreement dated June 16, 2006 for the allotment of 16.42 acres with Ramky Pharma City (India) and APIIC and also a development agreement with them, dated June 16, 2006 for development of land and infrastructure. It has already completed the implementation of the expansion plan in its Unit II. This expansion has enhanced the existing capacity of Unit II from the current level of 1250 MTPA to 2200 MTPA.
The company plans to establish new facility, compliant with international regulatory authorities like US FDA, WHO & EU. It seeks to capitalize on manufacturing of products, which are patent free in US and other regulatory market.